Immuno-oncology
Solution Focus

Immuno-oncology Solutions

Bioanalysis to Advanced Novel Cancer Treatment Options

Tumor diseases are one the most frequent causes of death in Western industrialized countries. Immune oncological approaches are helping to drive new levels of curative cancer treatment, and could possibly even lead to the eradication of most types of cancer, but development of these tools requires specific and sensitive bioanalytical methods and customized assays.

Find Answers to Your Immuno-oncology Questions:

Tell Us About Your Project

What are your specific assay needs? Let’s schedule a conversation to review your questions and requirements with one of our scientists.


Immuno-oncology Approaches: Leveraging the Immune System to Eliminate Cancer Cells

The clinical landscape for cancer is currently undergoing an exciting shift as the spectrum of available medicines has expanded beyond chemotherapy to a host of new molecularly targeted therapies. While in previous years all cell types were targeted by conventional therapeutics, novel drug options are targeting tumor cells only. Whereas drugs conjugated with specific antibodies (ADC, Antibody-Drug conjugates) bring the tumor-killing agent to its location to eliminate tumor cells only, novel immune oncological therapeutic options take advantage of the immune system to eliminate cancer cells.

The treatment of cancer by immunological tools can be tracked back to the early 1900s when Paul Ehrlich brought up the hypothesis that an intact immune system may protect from most cancers. These ideas led to the concept of immunosurveillance by Burnet and Thomas and immunoediting. With the understanding about the enormous diversity of both the humoral and cellular immune system and the recognition that the immunological players exist in all beings, it was a consequent idea to stimulate the immune system leading to a specific killing of cancer cells.

This molecular and possibly personalized approach may lead to the dusk of generic chemotherapies and to a new level of curative cancer treatment and possibly even to the eradication of most types of cancer.

 

shankar-paper

2014 Shankar, Kromminga et al. paper

Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides

For more information emphasizing associations of ADA development with pharmacokinetics, efficacy, and safety that are necessary to assess the clinical relevance of immunogenicity.

Download White Paper


Immune Oncological Tools: Exciting Therapeutic Options

With the increasing average life span of the population, 14 million new cases of cancer worldwide are diagnosed per year. The following examples are intended to demonstrate the immense power of immune oncological treatment options to address these cases, and are not mentioned to be a comprehensive overview nor a specific prioritization.

The first example are monoclonal antibodies which are directed against cancer-specific antigens, e.g. a monoclonal antibody directed against TYRP1, a protein which is highly expressed in melanocytes and melanoma cells. First results are highly promising that advanced malignant melanoma can be treated.

Another example of a promising immunotherapeutic approach are inhibitors of certain lymphocytes surface marker, e.g. NKTR-214 is a CD122 agonist designed to initiate a rapid proliferation of T- lymphocytes and Natural Killer (NK) cells. In addition, this molecule enhances the expression of PD-1 (programmed cell death protein 1) in these immune cells. Results of a Phase 1 study were recently presented at the 2016 annual meeting of the Society for Immunotherapy of Cancer.

Equally promising is the approach which should be paid attention on is the development of agent that interact with intracellular checkpoints such as PD-1 (programmed cell death protein 1) or LAG-3 (lymphocyte activation gene 3).

And finally, a cellular approach is the use of adoptive cell therapy (ACT) by the generation of chimeric antigen receptor T lymphocytes (CAR-T) which utilize patient’s tumor-infiltrating lymphocytes (TIL) to kill their own tumor cells. Novel molecular tools enable the specific design of these transformed cells. This approach widely opens the doors for personalized medicines.

immuno-oncology related services


Optimal Platforms for Immuno-Oncology Related Bioanalysis

All these novel molecular and specific humoral or cellular approaches which target different structure on cancer cells need to be monitored. Customized, specific ligand binding assays (LBA) with high sensitivity and specificity are needed to measure the efficacies of the treatment options. In general, multiplex or singleplex can be applied, often to assays based on the ECL technology. However, other bioanalytical tools are available including Luminex and others. The measurement of gene expressions is generally performed by quantitative real-time RT-PCR. Multi-color flow cytometry is used for the follow up analysis of cellular targets including lymphocyte differentiation. Multiplex or singleplex ELISPOT analysis is applied for the measurement of specific T- or B cell responses.

msd-ecl platform analytical device

MSD-ECL

luminex bio-plex platform analytical device

Luminex Bio-Plex

lightcycler platform analytical device

LightCycler

flow cytometry platform analytical device

Flow Cytometry
(FACS Analysis)

elispot platform analytical device

ELISPOT

biomarker offer

biomarker menu

Explore the Extensive BioAgilytix Biomarker Menu

Search our robust and ever-growing menu of over 400 biomarkers, including more than 120 validated biomarkers. We also have 100+ additional biomarker validations in the pipeline.

View Biomarker Menu


Make BioAgilytix the Partner to Progress Your Immuno-oncology Development Efforts

Immune oncological approaches are exciting tools to curatively treat and possibly eradicate cancer. Several humoral and cellular approaches are followed and are in clinical studies. These novel therapeutic tools require specific and sensitive bioanalytical methods and customized assays. On top of this, a clear and distinct clinical evaluation is needed.

BioAgilytix’s veteran scientists are working alongside leading pharma and biotech companies to advance promising immune oncological approaches and tools through expert bioanalysis. Let us help you realize the opportunities available in new molecularly targeted therapies for cancer treatment by leveraging our proven, seasoned scientific support.

immuno-oncology expertise


Speak to a Scientist

What would you like to discuss?

With whom will we be speaking?






Sign up for the quarterly newsletter?



biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies